Federation des caisses Desjardins du Quebec Reduces Stock Position in IQVIA Holdings Inc. $IQV

Key Points

• The Federation des caisses Desjardins du Quebec has reduced its stake in IQVIA Holdings Inc. by 38.8%, selling 26,857 shares during the first quarter, leaving them with 42,409 shares valued at approximately $7.48 million.
• Various institutional investors, including Canada Pension Plan Investment Board and JPMorgan Chase & Co., have increased their positions in IQVIA, with JPMorgan boosting its stake by 45.7%.
• IQVIA reported $2.81 earnings per share for the last quarter, exceeding estimates, and anticipates FY 2025 EPS guidance between $11.750 to $12.050, indicating expected growth.

Federation des caisses Desjardins du Quebec reduced its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,409 shares of the medical research company's stock after selling 26,857 shares during the quarter. Federation des caisses Desjardins du Quebec's holdings in IQVIA were worth $7,481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after acquiring an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. raised its stake in IQVIA by 45.7% during the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after purchasing an additional 798,534 shares in the last quarter. American Century Companies Inc. raised its stake in shares of IQVIA by 26.8% in the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock valued at $253,695,000 after acquiring an additional 304,258 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of IQVIA by 2.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after acquiring an additional 40,699 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of IQVIA by 13.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,393,140 shares of the medical research company's stock worth $273,766,000 after acquiring an additional 167,057 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on IQV shares. Barclays raised their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. UBS Group raised their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and lifted their price target for the company from $195.00 to $225.00 in a research note on Tuesday. Finally, Truist Financial lifted their price target on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Stock Performance

Shares of IQV stock traded up $1.38 during trading hours on Tuesday, hitting $189.06. The stock had a trading volume of 408,408 shares, compared to its average volume of 1,911,891. The firm has a market capitalization of $32.14 billion, a PE ratio of 27.36, a PEG ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03. The stock's 50 day moving average is $180.48 and its 200 day moving average is $167.20. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the prior year, the business earned $2.64 earnings per share. The company's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.